

Andreas Clemens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/570543/publications.pdf>

Version: 2024-02-01

22
papers

700
citations

1040056

9
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

900
citing authors

#	ARTICLE	IF	CITATIONS
1	Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study. <i>British Journal of Ophthalmology</i> , 2023, 107, 96-101.	3.9	5
2	Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study. <i>Eye</i> , 2022, 36, 1656-1661.	2.1	4
3	Brolucizumab 12- and 16-week fixed dosing potential in neovascular AMD: a post-hoc evaluation of data from the HAWK and HARRIER trials. <i>Ophthalmologica</i> , 2022, , .	1.9	0
4	Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2021, 244, 93-101.	1.9	82
5	Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. <i>Eye</i> , 2021, 35, 2119-2135.	2.1	25
6	Application of machine learning methods to bridge the gap between non-interventional studies and randomized controlled trials in ophthalmic patients with neovascular age-related macular degeneration. <i>Contemporary Clinical Trials</i> , 2021, 104, 106364.	1.8	7
7	Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort. <i>Clinical Research in Cardiology</i> , 2020, 109, 315-323.	3.3	39
8	<p>Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1729-1738.	2.3	11
9	Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study. <i>PLoS ONE</i> , 2020, 15, e0234739.	2.5	18
10	Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data. <i>Current Eye Research</i> , 2020, 45, 1298-1301.	1.5	9
11	Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study. <i>PLoS ONE</i> , 2020, 15, e0227557.	2.5	18
12	Differences in COPD Exacerbation Risk Between Women and Men. <i>Chest</i> , 2019, 156, 674-684.	0.8	19
13	Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 38.	2.6	27
14	Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach. <i>Contemporary Clinical Trials</i> , 2019, 80, 34-39.	1.8	1
15	Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018, 15, 185-191.	1.6	6
16	Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study. <i>Respiratory Research</i> , 2017, 18, 13.	3.6	5
17	Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single) Tj ETQq1 1,0,784314 rgBT /Que	1.8	8
18	Observational study of dabigatran etexilate 150 mg in patients with moderate renal impairment undergoing elective total hip or knee replacement. <i>Thrombosis Research</i> , 2016, 143, 103-110.	1.7	4

#	ARTICLE	IF	CITATIONS
19	Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting. <i>Thrombosis Journal</i> , 2016, 14, 8.	2.1	10
20	Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. <i>Thrombosis and Haemostasis</i> , 2012, 107, 838-847.	3.4	201
21	Real-World Study of Dabigatran Etexilate for Thromboprophylaxis in Over 5000 Hip or Knee Replacement Patients: Favourable Safety Profile in Subgroups with Different BMI, Renal Function and Age. <i>Blood</i> , 2012, 120, 1160-1160.	1.4	3
22	Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1885-1889.	2.4	198